heterologous vaccine
{{Short description|Vaccine using different types for priming and boosting}}
A homologous booster shot involves the administration of the same vaccine as previously administered, while a heterologous booster shot involves the administration of a different vaccine.{{cite journal |vauthors=Orlandi C, Stefanetti G, Barocci S, Buffi G, Diotallevi A, Rocchi E, Ceccarelli M, Peluso S, Vandini D, Carlotti E, Magnani M, Galluzzi L, Casabianca A |date=13 May 2023 |title=Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay |journal=Viruses |volume=15 |issue=5 |page=1162 |doi=10.3390/v15051162 |doi-access=free |pmc=10222288 |pmid=37243247}}
"Heterologous prime-boost immunization is administration of two different vectors or delivery systems expressing the same or overlapping antigenic inserts."{{cite web |title=WHO Technical Consultation: Heterologous Prime-Boost Immunization in Ebola vaccine development and testing, licensure and use; 21 November 2014 |url=https://www.who.int/immunization/research/meetings_workshops/Agenda_ebola_primeboost_nov14.pdf |website=World Health Organization |access-date=10 December 2021 |location=Geneva |date=2015-02-09 |archive-date=10 December 2021 |archive-url=https://web.archive.org/web/20211210211955/https://www.who.int/immunization/research/meetings_workshops/Agenda_ebola_primeboost_nov14.pdf |url-status=live }}
"An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens. In many cases such heterologous prime-boost can be more immunogenic than homologous prime-boost."{{cite journal |last1=Lu |first1=S |title=Heterologous prime-boost vaccination. |journal=Current Opinion in Immunology |date=June 2009 |volume=21 |issue=3 |pages=346–51 |doi=10.1016/j.coi.2009.05.016 |pmid=19500964|pmc=3743086 }}
References
{{Reflist}}
Further reading
- {{cite web |title=Interim statement on booster doses for COVID-19 vaccination |url=https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination |website=World Health Organization |language=en}}
- {{cite journal |vauthors=Liu X, Shaw RH, Stuart AS, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Dinesh T, England A, Faust SN, Ferreira DM, Finn A, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Lazarus R, Libri V, Long F, Mujadidi YF, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Singh N, Turner DP, Turner PJ, Walker LL, White R, Nguyen-Van-Tam JS, Snape MD |title=Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial |journal=The Lancet |date=4 September 2021 |volume=398 |issue=10303 |pages=856–869 |doi=10.1016/S0140-6736(21)01694-9 |pmid=34370971 |pmc=8346248 |language=English |issn=0140-6736}}
- {{cite web |last1=Mukherjee |first1=Debabrata |title=Heterologous vs. Homologous Prime-Boost Schedules for COVID-19 Vaccines |url=https://www.acc.org/latest-in-cardiology/journal-scans/2021/09/10/15/03/safety-and-immunogenicity |website=American College of Cardiology |quote=The authors concluded that the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against coronavirus disease 2019 (COVID-19) disease and hospitalization}}
{{Vaccines}}
{{vaccine-stub}}